MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
The Motley Fool
January 19, 2006
Stephen D. Simpson
Novartis Marches On While reported profits are masked by some charges, this Swiss drug company is still delivering the goods. Throw in a solid pipeline and a reasonable valuation, and the stock could still be worth a look for new money in the pharmaceutical space. mark for My Articles similar articles
Chemistry World
November 6, 2013
Laura Howes
Novartis to shut Horsham site Last year, the firm slammed the UK for the high cost of conducting clinical trials in the country, warning that business would leave unless more incentives were introduced to encourage firms to carry out R&D. mark for My Articles similar articles
The Motley Fool
April 21, 2005
Stephen D. Simpson
Novartis' Triple Threat The Swiss drug giant boasts strong franchises in generics, cardiology, and oncology. It's hard not to think of Novartis as one of the highest-quality options in the pharmaceutical investing space. mark for My Articles similar articles
The Motley Fool
October 23, 2006
Brian Lawler
No Slowing Novartis The Swiss pharmaceutical company shows strength in nearly all its divisions. Novartis looks like a good investment for risk-adverse investors searching for a large-cap pharma stock. mark for My Articles similar articles
The Motley Fool
January 29, 2009
Brian Orelli
Novartis: Diversification Isn't Good Enough Novartis has become a better diversified company, with acquisitions of vaccines specialist Chiron and 25% of eye-care specialist Alcon, but it's far from a cure all, as the fourth quarter showed. mark for My Articles similar articles
The Motley Fool
July 15, 2005
Stephen D. Simpson
Novartis' Over-the-Counter Tonic Novartis' latest purchase suggests a commitment to making itself a well-rounded pharma giant. Future margins may not be as high as they once were, but if the company can produce a lot more cash flow, investors won't mind a bit. mark for My Articles similar articles
The Motley Fool
June 6, 2008
Brian Lawler
Nothing Can Stop Novartis! Swiss pharmaceutical giant Novartis has bucketloads of cash, and apparently, it isn't afraid to use them. mark for My Articles similar articles
The Motley Fool
January 22, 2007
Brian Lawler
Another Busy Year in Store for Novartis Trying to place a value on Novartis is a tough thing to do now with so many important drugs awaiting regulatory review and its addiction to acquisitions and divestitures making financial comparisons between the years tough. mark for My Articles similar articles
The Motley Fool
July 17, 2006
Stephen D. Simpson
Novartis Pays for Its Shopping Spree Expenses from the Chiron acquisition bring down results for the second quarter. Investors, there's a lot to be said for waiting on the right price for even the best stocks out there. mark for My Articles similar articles
The Motley Fool
July 14, 2005
Stephen D. Simpson
These Swiss Don't Miss Aside from a hiccup in margins, Novartis' drug business continues to shine. This pharma is a solid middle-of-the-road play with reasonable valuation, a solid pipeline, and a not-so-secret weapon in its Sandoz generics business. mark for My Articles similar articles
The Motley Fool
July 16, 2009
Brian Orelli
A Strong Dollar Can Hurt Novartis makes it through a hard quarter. mark for My Articles similar articles
The Motley Fool
October 22, 2007
Brian Lawler
No Catastrophes at Novartis Novartis stays on track with its third-quarter results. Investors, take note. mark for My Articles similar articles
Chemistry World
November 14, 2013
Phillip Broadwith
Novartis sells off blood diagnostics division Swiss-based company Novartis has agreed to sell off its blood transfusion diagnostics unit to Spanish blood products specialist Grifols for $1.7 billion. mark for My Articles similar articles
The Motley Fool
September 1, 2005
Stephen D. Simpson
Novartis Keeps Gorging Offering to buy the remainder of Chiron for $4.5 billion may up this company's execution risk over the next few quarters. Investors, take note. mark for My Articles similar articles
Pharmaceutical Executive
November 1, 2006
Joanna Breitstein
Back Page: The Case for Diversity Variety is the spice of life - and the future of Big Pharma. mark for My Articles similar articles
The Motley Fool
July 21, 2004
Brian Gorman
Novartis Shows the Way It may be a model for other pharmaceutical outfits looking to improve productivity. mark for My Articles similar articles
The Motley Fool
July 16, 2010
Brian Orelli
A Positive Sign for Pharma Earnings Season Strong first-half results drove Novartis to increase its sales guidance for the year. mark for My Articles similar articles
The Motley Fool
October 21, 2008
Brian Orelli
Novartis Is Taking the Road Less Traveled Diversification should pay off for this pharma giant. mark for My Articles similar articles
The Motley Fool
July 28, 2011
Melly Alazraki
J&J or Novartis? Novartis' businesses are an investor's delight; J&J's improving but isn't there yet. mark for My Articles similar articles
The Motley Fool
September 20, 2005
Brian Gorman
Novartis Stays Focused New developments at the drug giant suggest the company is on track. Investors, take note. mark for My Articles similar articles
The Motley Fool
January 20, 2005
Stephen D. Simpson
Novartis Posts a Swiss Miss The Swiss drug giant has a strong pipeline, but moderate growth and high valuation suggest little room for error. mark for My Articles similar articles
The Motley Fool
April 25, 2007
Brian Lawler
Nothing Wrong With Novartis Novartis releases first-quarter financial results. Investors, take note. mark for My Articles similar articles
Chemistry World
October 1, 2013
Emma Stoye
Japan confirms Novartis clinical trial data fabrication Japan's ministry of health has concluded that studies based on clinical trials for Novartis's blood pressure drug Diovan contain manipulated data. It is now investigating whether the company has broken Japanese law by citing these studies to promote the product. mark for My Articles similar articles
The Motley Fool
January 4, 2010
Brian Orelli
You Don't Need Your Contacts In to See This Deal Novartis acts first to grab the rest of Nestle's stake in Alcon. mark for My Articles similar articles
The Motley Fool
October 31, 2005
Rich Duprey
Chiron Not Immune to Merger The board accepts a sweetened buyout offer from Swiss pharmaceutical firm Novartis. Investors, take note. mark for My Articles similar articles
The Motley Fool
October 18, 2005
Stephen D. Simpson
More Good News From Novartis This Swiss drug giant continues to post steady growth. Investors, take note. mark for My Articles similar articles
The Motley Fool
February 22, 2005
Brian Gorman
Novartis Embraces Generics The company is taking a different path from its branded pharmaceutical peers. The company's strategy may make its stock worth a closer look. mark for My Articles similar articles
Pharmaceutical Executive
November 1, 2008
No Ordinary Joe It's been a year since consumer marketing master Joe Jimenez took over the top spot at Novartis Pharma. How's he faring? mark for My Articles similar articles
The Motley Fool
January 27, 2010
Brian Orelli
Nice, Novartis, Very Nice CEO Daniel Vasella leaves on a high note. mark for My Articles similar articles
The Motley Fool
April 8, 2008
Brian Lawler
Novartis Sees More Growth Ahead Novartis makes one of the largest acquisitions in health-care history. mark for My Articles similar articles
Chemistry World
May 21, 2009
Matt Wilkinson
Big Pharma set for generics boost Pharmaceutical firms have been rushing to ensure they minimize their losses by expanding their generics businesses and reach into emerging markets. mark for My Articles similar articles
BusinessWeek
February 4, 2010
Dermot Doherty
The New Man at Novartis CEO Joe Jimenez says his consumer-products background, with stints at Clorox and Heinz, will be a booster for the drugmaker. mark for My Articles similar articles
Chemistry World
June 10, 2013
Phillip Broadwith
Sandoz manufacturing woes continue Sandoz, the generic drugs arm of Swiss firm Novartis, has had an official warning from the US Food and Drug Administration over failings at one of its manufacturing plants. mark for My Articles similar articles
The Motley Fool
July 14, 2008
Brian Orelli
Teva Gets a Taste of Its Own Medicine Momenta Pharmaceuticals and Novartis are challenging the patents on Teva Pharmaceutical's blockbuster multiple sclerosis drug Copaxone. mark for My Articles similar articles
The Motley Fool
June 7, 2004
Brian Gorman
Novartis Nabs Sabex Novartis' purchase gives it a lifeline to the generics market. mark for My Articles similar articles
The Motley Fool
December 19, 2006
Brian Gorman
Novartis Cuts in Line at the Drugstore Consolidation in pharmacy benefits management may leave Novartis most resistant to pricing pressure. Investors, take note. mark for My Articles similar articles
The Motley Fool
September 7, 2005
Rich Duprey
Is Chiron Worth It? The vaccine maker rejects Novartis' bid of $40 a share as inadequate. How much should the pharma pay? Investors, take note. mark for My Articles similar articles
Chemistry World
November 1, 2012
Andrew Turley
Novartis biotech plant for Singapore The new plant, which will make drugs through cell culture, will be located with the Novartis production plant at Tuas. mark for My Articles similar articles
The Motley Fool
November 12, 2009
Brian Orelli
How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way. mark for My Articles similar articles
The Motley Fool
April 14, 2005
Brian Gorman
Novartis Moves on Multiple Fronts Even with its investment in a potential blockbuster, Novartis remains remarkably diversified. Investors can rest assured, though, that the company's strategy won't leave it as vulnerable as other outfits. mark for My Articles similar articles
The Motley Fool
November 6, 2006
Brian Gorman
Novartis' China Gambit Novartis probably won't get any near-term dividend from its China investment, but the nation is too big to ignore. Investors, take note. mark for My Articles similar articles
Chemistry World
January 24, 2013
Andrew Turley
Vasella to leave Novartis in August Veteran pharma executive Danial Vasella has unexpectedly announced his resignation as chair of the board of directors at Novartis after 17 years at the top of the company. mark for My Articles similar articles
The Motley Fool
August 30, 2010
Brian Orelli
Maybe Not a Blockbuster, But We'll Take It Novartis' newest addition, blood pressure medication Tekamlo, isn't going to rocket to the top of the 2020 best seller list, but it's still a nice addition nonetheless. mark for My Articles similar articles
The Motley Fool
March 16, 2006
Rich Duprey
Chiron's Shareholder Revolt Hedge funds oppose the biotech's buyout by pharmaceutical giant Novartis. Investors, take note. mark for My Articles similar articles
The Motley Fool
June 22, 2007
Brian Lawler
Novartis' Good Week The pharma receives a pair of positive regulatory decisions. Investors, take note. mark for My Articles similar articles
Chemistry World
February 15, 2007
Victoria Gill
Novartis Contests India's Patent Law Swiss pharmaceutical company Novartis has accused the Indian government of failing to comply with WTO rules after it refused to grant the company a patent on its cancer drug Glivec. mark for My Articles similar articles
Managed Care
November 2004
Headlines On Deadline... What goes around comes around. At least that's what critics of the pharmaceutical industry seem to be saying as they gloat over reports that Novartis wants its employees to use more generic and over-the-counter medications. mark for My Articles similar articles
The Motley Fool
June 28, 2010
Brian Orelli
The Trouble Is They're Facing a Bazooka Alcon's minority shareholders are still fighting against Novartis' takeover. mark for My Articles similar articles
The Motley Fool
April 24, 2006
Stephen D. Simpson
Novartis: A Good Story Repeated Whether sales were a little light or not, this is still a high-quality pharmaceutical company. The company not only has a good pipeline, but the valuation is still attractive without needing to make particularly aggressive assumptions. mark for My Articles similar articles
Chemistry World
April 25, 2014
Andy Extance
$25bn-plus trade sharpens pharma giants' focus Three leading pharmaceutical firms are set to exchange business segments valued at over $25 billion, in deals affecting at least 14,000 employees. mark for My Articles similar articles